Incidence of aortic stenosis in subjects with normal and slightly elevated aortic gradients and flow

ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort stud...

Full description

Saved in:
Bibliographic Details
Published inHeart (British Cardiac Society) Vol. 101; no. 23; pp. 1895 - 1900
Main Authors Eveborn, Gry Wisthus, Schirmer, Henrik, Heggelund, Geir, Rasmussen, Knut
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group LTD 01.12.2015
Subjects
Online AccessGet full text
ISSN1355-6037
1468-201X
1468-201X
DOI10.1136/heartjnl-2015-307807

Cover

Loading…
Abstract ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5–9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10–15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.
AbstractList We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease. Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s). At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year. The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.
ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5–9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10–15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.
We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.OBJECTIVEWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).METHODSParticipants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient ≥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s).At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.RESULTSAt baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year.The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.CONCLUSIONSThe results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.
ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease.MethodsParticipants were recruited from the Tromsoe Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient greater than or equal to 15mmHg or a peak flow exceeding 2.6m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10mmHg) and peak aortic flow (cut-off 1.5 and 2m/s).ResultsAt baseline, 71 participants had gradients from 10 to 14.9mmHg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9mmHg and in 0.3% of those with a gradient <5mmHg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7mmHg/year.ConclusionsThe results support that subjects with a mean aortic valve gradient of 10-15mmHg or aortic flow >2.0m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7years.
Objective We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic valve disease. Methods Participants were recruited from the Tromsø Study, a population-based health survey. In our prospective cohort study, we performed two echocardiographical examinations (2001 and 2008) of a random sample of 1884 participants. AS was defined as a mean aortic valve gradient â[per thousand]¥15 mm Hg or a peak flow exceeding 2.6 m/s. Those with lesser values were stratified into three groups based on mean gradients (cut-off 5 and 10 mm Hg) and peak aortic flow (cut-off 1.5 and 2 m/s). Results At baseline, 71 participants had gradients from 10 to 14.9 mm Hg, of whom 32.4% developed AS during follow-up. AS developed in only 3.6% of those with a baseline gradient of 5-9.9 mm Hg and in 0.3% of those with a gradient <5 mm Hg. Almost identical separations were obtained among the three flow velocity groups. Of the 45 subjects who developed incident AS, 56% acquired mild, 33% moderate and 11% severe AS. Their mean gradient progression rate was 2.7 mm Hg/year. Conclusions The results support that subjects with a mean aortic valve gradient of 10-15 mm Hg or aortic flow >2.0 m/s should be followed routinely. This group identifies about half of those who develop AS in the following 7 years.
Author Rasmussen, Knut
Heggelund, Geir
Eveborn, Gry Wisthus
Schirmer, Henrik
Author_xml – sequence: 1
  givenname: Gry Wisthus
  surname: Eveborn
  fullname: Eveborn, Gry Wisthus
  email: gry.eveborn@unn.no
  organization: Division of Cardiothoracic and Respiratory Medicine, Department of Heart Disease, University Hospital of Northern Norway, Tromsø, Norway
– sequence: 2
  givenname: Henrik
  surname: Schirmer
  fullname: Schirmer, Henrik
  email: gry.eveborn@unn.no
  organization: Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
– sequence: 3
  givenname: Geir
  surname: Heggelund
  fullname: Heggelund, Geir
  email: gry.eveborn@unn.no
  organization: Division of Cardiothoracic and Respiratory Medicine, Department of Heart Disease, University Hospital of Northern Norway, Tromsø, Norway
– sequence: 4
  givenname: Knut
  surname: Rasmussen
  fullname: Rasmussen, Knut
  email: gry.eveborn@unn.no
  organization: Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26531820$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtr3TAQRkVJaB7tPyhF0E03TiRLtuzuSkjbQCCbFrozeoxyZWQpleSE_PvocnO7yCZZjRjOmUHznaCDEAMg9ImSM0pZf74BmcocfNMS2jWMiIGId-iY8n7Ytv4e1DfruqYnTByhk5xnQggfh_49Omr7jtGhJcfIXAXtDAQNOFosYypO41wgxOwydgHnVc2gS8YPrmxwiGmRHstgcPbudlP8IwYP97KA2du3SRoHoSpbzPr48AEdWukzfHyup-jPj8vfF7-a65ufVxffrxvFyVAaPVrLDaO6ZVwZOWjopFGqtyNoK6QeW8Gl7pTWyhpFtSAgRq46xUbKiWzZKfq6m3uX4r8VcpkWlzV4LwPENU90IEMvOjp0r6OCMTr2TIiKfnmBznFNoX6kUvXonPKRV-rzM7WqBcx0l9wi0-O0P3UF-A7QKeacwP5HKJm2iU77RKdtotMu0ap9e6FpV2RxMZQknX9NPt_Japnftu4Jsn-52w
CitedBy_id crossref_primary_10_1111_echo_14270
crossref_primary_10_1080_14017431_2016_1239837
crossref_primary_10_1136_heartjnl_2021_319697
crossref_primary_10_1136_openhrt_2021_001783
crossref_primary_10_3389_fcvm_2023_1170804
crossref_primary_10_1002_ehf2_13957
Cites_doi 10.1016/S0002-9149(98)00922-9
10.1016/S0002-9149(98)01064-9
10.1007/s10654-014-9936-x
10.1093/ije/dyr049
10.1136/heartjnl-2012-302265
10.1093/ejechocard/jen303
10.1161/CIRCULATIONAHA.104.486738
10.1016/j.jacc.2007.07.064
10.1016/S0735-1097(96)00563-3
10.1111/j.1365-2796.2011.02480.x
10.1161/CIRCULATIONAHA.106.176857
10.1001/archinte.162.20.2345
10.1016/0735-1097(93)90249-Z
10.1093/eurheartj/ehs109
10.1016/S0002-9149(02)03011-4
10.1136/hrt.54.4.396
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
– notice: Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
M0S
M1P
M2P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
7QO
8FD
FR3
P64
DOI 10.1136/heartjnl-2015-307807
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
BMJ Journals
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList MEDLINE

MEDLINE - Academic
Engineering Research Database
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-201X
EndPage 1900
ExternalDocumentID 4021187441
26531820
10_1136_heartjnl_2015_307807
heartjnl
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.VT
0R~
29I
2WC
354
39C
3O-
4.4
40O
53G
5GY
5RE
7X7
7~S
88E
88I
8AF
8FI
8FJ
8R4
8R5
AAFWJ
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAYEP
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABUWG
ABVAJ
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADUGQ
ADZCM
AEKJL
AENEX
AFFNX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZFZN
AZQEC
BAWUL
BCR
BENPR
BLC
BLJBA
BOMFT
BPHCQ
BTHHO
BVXVI
C1A
CAG
CCPQU
COF
CXRWF
DIK
DU5
DWQXO
E3Z
EBS
EJD
EX3
F5P
FEDTE
FYUFA
GNUQQ
GX1
H13
HAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
L7B
M1P
M2P
N4W
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PCD
PEA
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
TEORI
TR2
UKHRP
UYXKK
V24
VM9
WH7
WOQ
WOW
X7M
YFH
YQY
ZGI
ZXP
AAYXX
ACQHZ
ADGHP
AERUA
CITATION
PHGZM
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
Q9U
7X8
PUEGO
7QO
8FD
FR3
P64
ID FETCH-LOGICAL-b408t-c9ff4d31c234bda8ce5adbb6f9ecf7ac9274ac5bccbfdb1c70e794b5b39140a23
IEDL.DBID 7X7
ISSN 1355-6037
1468-201X
IngestDate Fri Sep 05 05:23:09 EDT 2025
Thu Sep 04 16:39:54 EDT 2025
Sat Jul 26 02:40:11 EDT 2025
Thu Apr 03 07:05:57 EDT 2025
Thu Apr 24 22:57:48 EDT 2025
Tue Jul 01 04:32:17 EDT 2025
Thu Apr 24 22:50:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 23
Language English
License Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b408t-c9ff4d31c234bda8ce5adbb6f9ecf7ac9274ac5bccbfdb1c70e794b5b39140a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 26531820
PQID 1780741494
PQPubID 2041068
PageCount 6
ParticipantIDs proquest_miscellaneous_1808675185
proquest_miscellaneous_1733196377
proquest_journals_1780741494
pubmed_primary_26531820
crossref_primary_10_1136_heartjnl_2015_307807
crossref_citationtrail_10_1136_heartjnl_2015_307807
bmj_primary_10_1136_heartjnl_2015_307807
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20151200
2015-12-01
2015-Dec
20151201
PublicationDateYYYYMMDD 2015-12-01
PublicationDate_xml – month: 12
  year: 2015
  text: 20151200
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Heart (British Cardiac Society)
PublicationTitleAlternate Heart
PublicationYear 2015
Publisher BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group LTD
References Bodegard, Skretteberg, Gjesdal 2012; 271
Lindroos, Kupari, Heikkila 1993; 21
Stewart, Siscovick, Lind 1997; 29
Eveborn, Schirmer, Heggelund 2013; 99
Baumgartner, Hung, Bermejo 2009; 10
Singh, Evans, Levy 1999; 83
Novaro, Katz, Aviles 2007; 50
Freeman, Otto 2005; 111
Faggiano, Antonini-Canterin, Erlicher 2003; 91
Bonow, Carabello, Kanu 2006; 114
Aronow, Ahn, Shirani 1999; 83
Eveborn, Schirmer, Lunde 2014; 29
Hegrenaes, Hatle 1985; 54
Jacobsen, Eggen, Mathiesen 2012; 41
Vahanian, Alfieri, Andreotti 2012; 33
Cosmi, Kort, Tunick 2002; 162
References_xml – volume: 83
  start-page: 599
  year: 1999
  article-title: Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis
  publication-title: Am J Cardiol
  doi: 10.1016/S0002-9149(98)00922-9
– volume: 83
  start-page: 897
  year: 1999
  article-title: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)
  publication-title: Am J Cardiol
  doi: 10.1016/S0002-9149(98)01064-9
– volume: 29
  start-page: 567
  year: 2014
  article-title: Assessment of risk factors for developing incident aortic stenosis: the Tromsø study
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-014-9936-x
– volume: 41
  start-page: 961
  year: 2012
  article-title: Cohort profile: the Tromso study
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyr049
– volume: 99
  start-page: 396
  year: 2013
  article-title: The evolving epidemiology of valvular aortic stenosis. The Tromsø study
  publication-title: Heart
  doi: 10.1136/heartjnl-2012-302265
– volume: 10
  start-page: 1
  year: 2009
  article-title: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice
  publication-title: Eur J Echocardiogr
  doi: 10.1093/ejechocard/jen303
– volume: 111
  start-page: 3316
  year: 2005
  article-title: Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.104.486738
– volume: 50
  start-page: 1992
  year: 2007
  article-title: Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2007.07.064
– volume: 29
  start-page: 630
  year: 1997
  article-title: Clinical factors associated with calcific aortic valve disease.
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(96)00563-3
– volume: 271
  start-page: 581
  year: 2012
  article-title: Low-grade systolic murmurs in healthy middle-aged individuals: innocent or clinically significant? A 35-year follow-up study of 2014 Norwegian men
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2011.02480.x
– volume: 114
  start-page: e84
  year: 2006
  article-title: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.106.176857
– volume: 162
  start-page: 2345
  year: 2002
  article-title: The risk of the development of aortic stenosis in patients with “benign” aortic valve thickening
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.162.20.2345
– volume: 21
  start-page: 1220
  year: 1993
  article-title: Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample
  publication-title: J Am Coll Cardiol
  doi: 10.1016/0735-1097(93)90249-Z
– volume: 33
  start-page: 2451
  year: 2012
  article-title: Guidelines on the management of valvular heart disease (version 2012)
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehs109
– volume: 91
  start-page: 99
  year: 2003
  article-title: Progression of aortic valve sclerosis to aortic stenosis
  publication-title: Am J Cardiol
  doi: 10.1016/S0002-9149(02)03011-4
– volume: 54
  start-page: 396
  year: 1985
  article-title: Aortic stenosis in adults. Non-invasive estimation of pressure differences by continuous wave Doppler echocardiography
  publication-title: Br Heart J
  doi: 10.1136/hrt.54.4.396
SSID ssj0004986
Score 2.2018325
Snippet ObjectiveWe aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific...
We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific aortic...
Objective We aimed to describe the progression rate into manifest aortic stenosis (AS) in subjects with normal aortic valves or in an early phase of calcific...
SourceID proquest
pubmed
crossref
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1895
SubjectTerms Adult
Aged
Aged, 80 and over
Aorta - diagnostic imaging
Aorta - physiopathology
Aortic Valve - diagnostic imaging
Aortic Valve - physiopathology
Aortic Valve Stenosis - diagnosis
Aortic Valve Stenosis - epidemiology
Aortic Valve Stenosis - physiopathology
Blood Flow Velocity
Disease
Disease Progression
Echocardiography, Doppler, Color - methods
Female
Follow-Up Studies
Health Surveys
Hospitals
Humans
Medical prognosis
Middle Aged
Morphology
Multivariate analysis
Norway - epidemiology
Older people
Population
Population Surveillance
Proportional Hazards Models
Survival analysis
Velocity
Title Incidence of aortic stenosis in subjects with normal and slightly elevated aortic gradients and flow
URI https://heart.bmj.com/content/101/23/1895.full
https://www.ncbi.nlm.nih.gov/pubmed/26531820
https://www.proquest.com/docview/1780741494
https://www.proquest.com/docview/1733196377
https://www.proquest.com/docview/1808675185
Volume 101
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NaxUxEA-2BfEifvu0lggevITuviSbzUlUWorQImLh3ZZ8Ssuard33EP97Z7LZVzxYPe-EDZOZyW8myfwIeVNpr2VYNixqq5lQ0jNTu8CEiwI2OB-ixIfCp2fNybn4tJKrUnAby7XKOSbmQO0HhzXyw1ph2xbA8-Ld1Q-GrFF4ulooNHbIXm5dBvasVurmXaTOTI817KmsqbgqT-dq3hwiXfT6MvVgJbXEAkyLhLI79vvlnxvUX1Bn3n2OH5D7BTbS99M6PyR3QnpE7p6Wg_HHxIOfT_SgdIjUDChHYQHTMF6M9CLRcWOx4jJSLLzShEi1pyZ5CjgT0vP-F8WH5gA8_Tz623W-DQZDUCz2w88n5Pz46OvHE1YIFJgVVbtmTscoPK_dkgvrTeuCNN7aJurgojJOQ0pqnLTO2eht7VQVwD2ttFxD3mWW_CnZTUMKzwn1LQ-65pFDPilUC-GaV6aKDuCTsdpXC_IWdNddTS0yupxa8Kab1dyhmrtJzQvCZwV3rjQiRz6M_h-j2HbU__1lf167rrjl2N0Y0YK83n4Gh8JTEpPCsEEZnsOSUrfItJAJ4oGVXJBnk11sJ7VsIKwBrnpx-wReknvZ9PLNmH2yu77ehFeAb9b2IBvxAdn7cHT2-ctv8jD7jg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxRBEO7gkqgXgy9cBW0TTbx0mJnuefTBEFDIIuzGGEi4jf1EyDiDzGwIf8rfSNU8lngQvXCe7kyn-uuqr6q6ugh5F0grYxclzEstmUhjy1RoHBPGCzBw1vkYC4Wns2RyJL4cx8dL5PdQC4PXKged2CpqWxmMkW-EKT7bAnxebJ7_Ytg1CrOrQwuNDhb77uoSXLb6495n2N_3UbS7c_hpwvquAkyLIGuYkd4Ly0MTcaGtyoyLldU68dIZnyojwU9TJtbGaG91aNLAAWZ1rLkEZ0ThQweg8pcFVrSOyPL2zuzrt5tKTNn2lgzBirMk4GlfrBfyZAMbVDdnZQG4DGMM-WTYwvae_nn2p0n8C89t7d3uCnnUE1W61SHrMVly5RNyf9qn4p8SC5qla0hKK09VheMoQKas6tOanpa0nmuM8dQUQ720RG5cUFVaCsz25EdTXFEsbQeqa4fZJxft_TOYgsN8UV0-I0d3ItznZFRWpXtBqM24kyH3HDxYkWZgIHigAm-AsCktbTAmH0B2-Xn3KEfeOjM8yQcx5yjmvBPzmPBBwLnpnz7HDhzFP2axxaz_-8vasHd5rwjq_Aa2Y_J28RmOMOZlVOmqOY7hrSJM01vGZOB7YoosHpPVDheLRUUJKFJgci9vX8Ab8mByOD3ID_Zm-6_IwxaG7b2cNTJqLuZuHdhVo1_3kKbk-12fomvkyju-
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouqLy3LWAkkLhYm8RxHB8qhCirltKKA5X2FvwsrULSNllV_Wv9dczksRUHCpeeM1as8eeZb2zPDCFvI-WU8EnGgjKKpVI4pmPrWWpDCg7O-SAwUfjgMNs9Sr_MxXyFXI-5MPiscrSJnaF2tcUz8mkssWwL8Pl0GoZnEd92Zh_Ozhl2kMKb1rGdRg-RfX91CeFbs723A2v9Lklmn79_2mVDhwFm0ihvmVUhpI7HNuGpcTq3XmhnTBaUt0FqqyBm01YYa01wJrYy8oBfIwxXEJhoLHoA5v--5MCqYC_JubzJyVRdl8kY_DnLIi6HtL2YZ1NsVd2eViUgNBZ4-JNjM9t75tfpn87xL4y383yzdfJwoKz0Y4-xR2TFV4_J2sFwKf-EOLAxfWtSWgeqa5SjAJ6qbk4aelLRZmHwtKeheOhLK2TJJdWVo8Bxj3-25RXFJHcgvW4cfXzRvUSDISgWyvryKTm6E9U-I6tVXfkXhLqcexXzwCGWTWUOroJHOgoWqJs2ykUT8h50V5z15TmKLqzhWTGquUA1F72aJ4SPCi7sUAQde3GU_xjFlqP-7y9b49oVg0loihsAT8ib5WfYzHhDoytfL1CGdyZRyltkcohC8bJMTMjzHhfLSSUZmFTgdBu3T-A1WYO9U3zdO9zfJA86FHYPdLbIanux8C-BZrXmVYdnSn7c9Qb6DdXKPoU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+aortic+stenosis+in+subjects+with+normal+and+slightly+elevated+aortic+gradients+and+flow&rft.jtitle=Heart+%28British+Cardiac+Society%29&rft.au=Eveborn%2C+Gry+Wisthus&rft.au=Schirmer%2C+Henrik&rft.au=Heggelund%2C+Geir&rft.au=Rasmussen%2C+Knut&rft.date=2015-12-01&rft.eissn=1468-201X&rft.volume=101&rft.issue=23&rft.spage=1895&rft_id=info:doi/10.1136%2Fheartjnl-2015-307807&rft_id=info%3Apmid%2F26531820&rft.externalDocID=26531820
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1355-6037&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1355-6037&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1355-6037&client=summon